Filing Analysis
The Oncology Institute, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected eight directors, ratified the appointment of BDO USA, P.C. as independent auditors, and approved advisory proposals regarding executive compensation (Say-on-Pay and Say-on-Frequency).
📋 Key Facts
- Annual Meeting held on June 17, 2026.
- Voter turnout was 75.26% (75,242,437 shares voted out of 99,982,933 outstanding).
- Eight directors were elected: Brad Hively, Karen Johnson, Mohit Kaushal, Anne McGeorge, Mark Pacala, Mark Stolper, Kimberly Tzoumakas, and Daniel Virnich.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The 'Say-on-Pay' proposal was approved.
- The 'Say-on-Frequency' proposal was approved, with the company committing to hold advisory votes on executive compensation annually.
The Oncology Institute, Inc. (TOI) filed an 8-K under Item 1.05 (Material Cybersecurity Incidents) disclosing that a third-party vendor suffered a cybersecurity breach that compromised patient personal information. This filing is a follow-up to a voluntary disclosure made on November 6, 2025, and was triggered by notification from Kroll (the vendor's third-party administrator) on May 20, 2026, confirming unauthorized access to Company systems including patient data. The Company states that as of the filing date, the incident has not had a material impact on operations, financial systems, or quality of care, but the investigation and assessment remain ongoing.
🚩 Red Flags
- Confirmed patient personal data breach — significant HIPAA exposure and potential OCR (HHS Office for Civil Rights) investigation risk in the healthcare context
- ~6.5-month gap between initial voluntary disclosure (Nov 6, 2025) and confirmed breach notification (May 20, 2026), raising questions about vendor transparency and incident response timelines
- Investigation explicitly described as 'ongoing' — material financial and reputational impacts cannot yet be ruled out
- Risk of regulatory inquiries, class-action litigation, and patient notification obligations under state and federal breach laws (HIPAA, HITECH, state breach statutes)
- Vendor-driven breach (third-party supply chain risk) limits Company's direct control over remediation and disclosure timelines
- Company is evaluating 'any other material impact, if any, including on its financial condition or results of operations' — explicit acknowledgment of unquantified financial risk
- Reservation of claims against third parties signals potential costly legal proceedings ahead
- Healthcare sector breaches typically carry elevated regulatory and litigation costs, particularly for micro-cap companies with limited resources
📋 Key Facts
- Filing date: May 22, 2026; incident notification received: May 20, 2026
- Item 1.05 (Material Cybersecurity Incidents) triggered — mandatory SEC cybersecurity disclosure under rules adopted in 2023
- Prior voluntary disclosure was made under Item 7.01 on November 6, 2025, approximately 6.5 months before this mandatory follow-up
- Kroll, acting as third-party administrator for the unnamed Vendor, notified TOI on May 20, 2026 of confirmed unauthorized access to Company systems
- Breach confirmed to include systems affecting patient personal data
- Company believes incident has affected 'various other healthcare service providers,' suggesting a supply-chain/multi-victim breach
- Vendor has established a patient portal for information and inquiries
- Company will work with Vendor to offer credit monitoring and identity protection to impacted patients
- Company reserves all rights with respect to potential claims against the Vendor and other third parties
- Company states incident has not had a material impact on operations, financial systems, or quality of care as of the filing date
- Investigation and assessment described as 'ongoing' — potential for additional material disclosures
- Signed by Minh Merchant, Chief Legal Officer, on May 22, 2026
The Oncology Institute, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release furnished in this filing.
📋 Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results is included as Exhibit 99.1.
- The report was signed by Robert Carter, the Chief Financial Officer, on May 7, 2026.
The Oncology Institute, Inc. furnished an updated investor presentation dated March 13, 2026, for use in upcoming investor meetings. The filing is a routine disclosure under Regulation FD to ensure public access to information shared with private investors.
📋 Key Facts
- The company furnished an investor presentation as Exhibit 99.1 on March 13, 2026.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by Robert Carter, the Chief Financial Officer.
- The company's common stock (TOI) and redeemable warrants (TOIIW) are listed on the Nasdaq Stock Market.
The Oncology Institute, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The information was provided via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report covers financial results for the quarter and fiscal year ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The press release is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
The Oncology Institute, Inc. appointed Kimberly Tzoumakas to its Board of Directors effective February 23, 2026. Ms. Tzoumakas is an independent director who will receive standard non-employee director compensation including a $75,000 annual retainer and future RSU grants.
📋 Key Facts
- Kimberly Tzoumakas appointed to the Board effective February 23, 2026
- Director meets Nasdaq independence requirements
- Annual cash compensation of $75,000 plus future RSU grants
- No reportable related-party transactions or conflicts of interest identified